CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

Stock Information for CDT Equity Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CDT Equity Inc.

CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
CDT Positions for Transformational Growth
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.